THYROLAR-0.5
LOE ApproachingNDAORALTABLET
Approved
Nov 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYROLAR-0.5 is an oral tablet thyroid hormone replacement therapy approved in 1969. The product treats hypothyroidism and related thyroid disorders. The mechanism of action involves thyroid hormone supplementation to restore normal metabolic function.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential team restructuring and transition planning activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
THYROLAR-0.5 positions are likely in defensive, cost-management, and market-maintenance functions rather than growth-oriented roles. Career advancement on this product may be limited due to mature lifecycle and approaching LOE.
Brand ManagerManaged Care Analyst
Worked on THYROLAR-0.5 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.